This study innovatively explored the role of serum SV2A in patients with AD by the Simoa, which will promote the application of the marker in more fields, including early screening, differential diagnosis, and treatment monitoring of AD, and provide a new technical tool for the study of SV2A in other neurodegenerative diseases. Here, SV2A is linked to Alzheimer disease.